This antibody showed in first proof-of-concept studies potent anti-myeloma activity comparable to the clinically approved CD38 IgG1 antibodies daratumumab and isatuximab used for MM immunotherapy. This evidence concerns the gene CD38 and Miyoshi myopathy.